Review



cell lines u266 pir  (JCRB Cell Bank)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    JCRB Cell Bank cell lines u266 pir
    Drug-library screening in multiple myeloma cell lines identifies EHMT2 inhibition as synthetic lethal to the proteasome inhibitor carfilzomib. Experimental design of the drug-library screening. Primary screening was performed on <t>U266</t> PIR cell line. The top 40 candidates were selected using excess over Bliss (EOB) value (cut-off ≥ 0.4) and subjected to a secondary screening that was performed on U266 PIR , U266, KMM-1, AMO-1, and KMS28-BM cell lines. The EHMT2 inhibitor UNC0642 ranked among the top ten candidates, being synergistic with CFZ in five out of five cell lines at two or more different concentrations (Created by BioRender.com accessed on 26 February 2023).
    Cell Lines U266 Pir, supplied by JCRB Cell Bank, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cell+lines+u266+pir/cell+lines+u266+pir/pmc10137151-76-7-20
    Average 90 stars, based on 1 article reviews
    cell lines u266 pir - by Bioz Stars, 2026-09
    90/100 stars

    Images

    1) Product Images from "Euchromatic Histone Lysine Methyltransferase 2 Inhibition Enhances Carfilzomib Sensitivity and Overcomes Drug Resistance in Multiple Myeloma Cell Lines"

    Article Title: Euchromatic Histone Lysine Methyltransferase 2 Inhibition Enhances Carfilzomib Sensitivity and Overcomes Drug Resistance in Multiple Myeloma Cell Lines

    Journal: Cancers

    doi: 10.3390/cancers15082199

    Drug-library screening in multiple myeloma cell lines identifies EHMT2 inhibition as synthetic lethal to the proteasome inhibitor carfilzomib. Experimental design of the drug-library screening. Primary screening was performed on U266 PIR cell line. The top 40 candidates were selected using excess over Bliss (EOB) value (cut-off ≥ 0.4) and subjected to a secondary screening that was performed on U266 PIR , U266, KMM-1, AMO-1, and KMS28-BM cell lines. The EHMT2 inhibitor UNC0642 ranked among the top ten candidates, being synergistic with CFZ in five out of five cell lines at two or more different concentrations (Created by BioRender.com accessed on 26 February 2023).
    Figure Legend Snippet: Drug-library screening in multiple myeloma cell lines identifies EHMT2 inhibition as synthetic lethal to the proteasome inhibitor carfilzomib. Experimental design of the drug-library screening. Primary screening was performed on U266 PIR cell line. The top 40 candidates were selected using excess over Bliss (EOB) value (cut-off ≥ 0.4) and subjected to a secondary screening that was performed on U266 PIR , U266, KMM-1, AMO-1, and KMS28-BM cell lines. The EHMT2 inhibitor UNC0642 ranked among the top ten candidates, being synergistic with CFZ in five out of five cell lines at two or more different concentrations (Created by BioRender.com accessed on 26 February 2023).

    Techniques Used: Drug discovery, Inhibition

    EHMT2 inhibition synergically increases proteasome inhibitor-mediated cell death in PI-resistant and PI-sensitive multiple myeloma cell lines. ( a ) Heatmap representing cell viability after single and combinatorial treatment in U266 PIR -, KMM1 PIR -, AMO1 PIR -, RPMI PIRBTZ -, and RPMI PIRCFZ -resistant cell lines and U266-, KMM-1-, KMS28-BM-, AMO-1-, RPMI-8226-, and OPM-2-sensitive cell lines. Analysis was performed 72 h post-treatment with FACS or the CellTiterGlo assay ( n = 3). ( b – d ) SynergyFinder analysis of UNC0642/CFZ dose–response matrixes. Percentage of inhibition was retrieved with the CellTiter Glo assay 72 h post-treatment and normalized to the luminescent signal measured at day 0. Synergy score was calculated with Bliss.
    Figure Legend Snippet: EHMT2 inhibition synergically increases proteasome inhibitor-mediated cell death in PI-resistant and PI-sensitive multiple myeloma cell lines. ( a ) Heatmap representing cell viability after single and combinatorial treatment in U266 PIR -, KMM1 PIR -, AMO1 PIR -, RPMI PIRBTZ -, and RPMI PIRCFZ -resistant cell lines and U266-, KMM-1-, KMS28-BM-, AMO-1-, RPMI-8226-, and OPM-2-sensitive cell lines. Analysis was performed 72 h post-treatment with FACS or the CellTiterGlo assay ( n = 3). ( b – d ) SynergyFinder analysis of UNC0642/CFZ dose–response matrixes. Percentage of inhibition was retrieved with the CellTiter Glo assay 72 h post-treatment and normalized to the luminescent signal measured at day 0. Synergy score was calculated with Bliss.

    Techniques Used: Inhibition, Glo Assay

    Related Articles

    Generated:

    Article Title: Euchromatic Histone Lysine Methyltransferase 2 Inhibition Enhances Carfilzomib Sensitivity and Overcomes Drug Resistance in Multiple Myeloma Cell Lines
    Article Snippet: Human multiple myeloma (MM) cell lines KMM-1, U266, OPM-2, KMS28-BM, U266 PIR , and KMM1 PIR were obtained from the Japanese Collection of Research Bioresources Cell Bank (JCRB), National Institutes of Biomedical Innovation, Health and Nutrition, Ibakari, Osaka, Japan; the Leibniz Institute-German Collection of Microorganisms and Cell Cultures GmbH (DSMZ), Braunschweig, Germany; or generated in our lab and authenticated by DNA fingerprinting using the GenePrint system (Promega, Madison, WI, USA).

    DNA Profiling:

    Article Title: Euchromatic Histone Lysine Methyltransferase 2 Inhibition Enhances Carfilzomib Sensitivity and Overcomes Drug Resistance in Multiple Myeloma Cell Lines
    Article Snippet: Human multiple myeloma (MM) cell lines KMM-1, U266, OPM-2, KMS28-BM, U266 PIR , and KMM1 PIR were obtained from the Japanese Collection of Research Bioresources Cell Bank (JCRB), National Institutes of Biomedical Innovation, Health and Nutrition, Ibakari, Osaka, Japan; the Leibniz Institute-German Collection of Microorganisms and Cell Cultures GmbH (DSMZ), Braunschweig, Germany; or generated in our lab and authenticated by DNA fingerprinting using the GenePrint system (Promega, Madison, WI, USA).

    Drug discovery:

    Article Title: Euchromatic Histone Lysine Methyltransferase 2 Inhibition Enhances Carfilzomib Sensitivity and Overcomes Drug Resistance in Multiple Myeloma Cell Lines
    Article Snippet: Human multiple myeloma (MM) cell lines KMM-1, U266, OPM-2, KMS28-BM, U266 PIR , and KMM1 PIR were obtained from the Japanese Collection of Research Bioresources Cell Bank (JCRB), National Institutes of Biomedical Innovation, Health and Nutrition, Ibakari, Osaka, Japan; the Leibniz Institute-German Collection of Microorganisms and Cell Cultures GmbH (DSMZ), Braunschweig, Germany; or generated in our lab and authenticated by DNA fingerprinting using the GenePrint system (Promega, Madison, WI, USA).

    Inhibition:

    Article Title: Euchromatic Histone Lysine Methyltransferase 2 Inhibition Enhances Carfilzomib Sensitivity and Overcomes Drug Resistance in Multiple Myeloma Cell Lines
    Article Snippet: Human multiple myeloma (MM) cell lines KMM-1, U266, OPM-2, KMS28-BM, U266 PIR , and KMM1 PIR were obtained from the Japanese Collection of Research Bioresources Cell Bank (JCRB), National Institutes of Biomedical Innovation, Health and Nutrition, Ibakari, Osaka, Japan; the Leibniz Institute-German Collection of Microorganisms and Cell Cultures GmbH (DSMZ), Braunschweig, Germany; or generated in our lab and authenticated by DNA fingerprinting using the GenePrint system (Promega, Madison, WI, USA).

    Glo Assay:

    Article Title: Euchromatic Histone Lysine Methyltransferase 2 Inhibition Enhances Carfilzomib Sensitivity and Overcomes Drug Resistance in Multiple Myeloma Cell Lines
    Article Snippet: Human multiple myeloma (MM) cell lines KMM-1, U266, OPM-2, KMS28-BM, U266 PIR , and KMM1 PIR were obtained from the Japanese Collection of Research Bioresources Cell Bank (JCRB), National Institutes of Biomedical Innovation, Health and Nutrition, Ibakari, Osaka, Japan; the Leibniz Institute-German Collection of Microorganisms and Cell Cultures GmbH (DSMZ), Braunschweig, Germany; or generated in our lab and authenticated by DNA fingerprinting using the GenePrint system (Promega, Madison, WI, USA).



    Similar Products

    cell lines u266 pir  (JCRB Cell Bank)
    90
    JCRB Cell Bank cell lines u266 pir
    Drug-library screening in multiple myeloma cell lines identifies EHMT2 inhibition as synthetic lethal to the proteasome inhibitor carfilzomib. Experimental design of the drug-library screening. Primary screening was performed on <t>U266</t> PIR cell line. The top 40 candidates were selected using excess over Bliss (EOB) value (cut-off ≥ 0.4) and subjected to a secondary screening that was performed on U266 PIR , U266, KMM-1, AMO-1, and KMS28-BM cell lines. The EHMT2 inhibitor UNC0642 ranked among the top ten candidates, being synergistic with CFZ in five out of five cell lines at two or more different concentrations (Created by BioRender.com accessed on 26 February 2023).
    Cell Lines U266 Pir, supplied by JCRB Cell Bank, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cell+lines+u266+pir/cell+lines+u266+pir/pmc10137151-76-7-20
    Average 90 stars, based on 1 article reviews
    cell lines u266 pir - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Drug-library screening in multiple myeloma cell lines identifies EHMT2 inhibition as synthetic lethal to the proteasome inhibitor carfilzomib. Experimental design of the drug-library screening. Primary screening was performed on U266 PIR cell line. The top 40 candidates were selected using excess over Bliss (EOB) value (cut-off ≥ 0.4) and subjected to a secondary screening that was performed on U266 PIR , U266, KMM-1, AMO-1, and KMS28-BM cell lines. The EHMT2 inhibitor UNC0642 ranked among the top ten candidates, being synergistic with CFZ in five out of five cell lines at two or more different concentrations (Created by BioRender.com accessed on 26 February 2023).

    Journal: Cancers

    Article Title: Euchromatic Histone Lysine Methyltransferase 2 Inhibition Enhances Carfilzomib Sensitivity and Overcomes Drug Resistance in Multiple Myeloma Cell Lines

    doi: 10.3390/cancers15082199

    Figure Lengend Snippet: Drug-library screening in multiple myeloma cell lines identifies EHMT2 inhibition as synthetic lethal to the proteasome inhibitor carfilzomib. Experimental design of the drug-library screening. Primary screening was performed on U266 PIR cell line. The top 40 candidates were selected using excess over Bliss (EOB) value (cut-off ≥ 0.4) and subjected to a secondary screening that was performed on U266 PIR , U266, KMM-1, AMO-1, and KMS28-BM cell lines. The EHMT2 inhibitor UNC0642 ranked among the top ten candidates, being synergistic with CFZ in five out of five cell lines at two or more different concentrations (Created by BioRender.com accessed on 26 February 2023).

    Article Snippet: Human multiple myeloma (MM) cell lines KMM-1, U266, OPM-2, KMS28-BM, U266 PIR , and KMM1 PIR were obtained from the Japanese Collection of Research Bioresources Cell Bank (JCRB), National Institutes of Biomedical Innovation, Health and Nutrition, Ibakari, Osaka, Japan; the Leibniz Institute-German Collection of Microorganisms and Cell Cultures GmbH (DSMZ), Braunschweig, Germany; or generated in our lab and authenticated by DNA fingerprinting using the GenePrint system (Promega, Madison, WI, USA).

    Techniques: Drug discovery, Inhibition

    EHMT2 inhibition synergically increases proteasome inhibitor-mediated cell death in PI-resistant and PI-sensitive multiple myeloma cell lines. ( a ) Heatmap representing cell viability after single and combinatorial treatment in U266 PIR -, KMM1 PIR -, AMO1 PIR -, RPMI PIRBTZ -, and RPMI PIRCFZ -resistant cell lines and U266-, KMM-1-, KMS28-BM-, AMO-1-, RPMI-8226-, and OPM-2-sensitive cell lines. Analysis was performed 72 h post-treatment with FACS or the CellTiterGlo assay ( n = 3). ( b – d ) SynergyFinder analysis of UNC0642/CFZ dose–response matrixes. Percentage of inhibition was retrieved with the CellTiter Glo assay 72 h post-treatment and normalized to the luminescent signal measured at day 0. Synergy score was calculated with Bliss.

    Journal: Cancers

    Article Title: Euchromatic Histone Lysine Methyltransferase 2 Inhibition Enhances Carfilzomib Sensitivity and Overcomes Drug Resistance in Multiple Myeloma Cell Lines

    doi: 10.3390/cancers15082199

    Figure Lengend Snippet: EHMT2 inhibition synergically increases proteasome inhibitor-mediated cell death in PI-resistant and PI-sensitive multiple myeloma cell lines. ( a ) Heatmap representing cell viability after single and combinatorial treatment in U266 PIR -, KMM1 PIR -, AMO1 PIR -, RPMI PIRBTZ -, and RPMI PIRCFZ -resistant cell lines and U266-, KMM-1-, KMS28-BM-, AMO-1-, RPMI-8226-, and OPM-2-sensitive cell lines. Analysis was performed 72 h post-treatment with FACS or the CellTiterGlo assay ( n = 3). ( b – d ) SynergyFinder analysis of UNC0642/CFZ dose–response matrixes. Percentage of inhibition was retrieved with the CellTiter Glo assay 72 h post-treatment and normalized to the luminescent signal measured at day 0. Synergy score was calculated with Bliss.

    Article Snippet: Human multiple myeloma (MM) cell lines KMM-1, U266, OPM-2, KMS28-BM, U266 PIR , and KMM1 PIR were obtained from the Japanese Collection of Research Bioresources Cell Bank (JCRB), National Institutes of Biomedical Innovation, Health and Nutrition, Ibakari, Osaka, Japan; the Leibniz Institute-German Collection of Microorganisms and Cell Cultures GmbH (DSMZ), Braunschweig, Germany; or generated in our lab and authenticated by DNA fingerprinting using the GenePrint system (Promega, Madison, WI, USA).

    Techniques: Inhibition, Glo Assay